Research programme: antibody therapeutics - Medarex

Drug Profile

Research programme: antibody therapeutics - Medarex

Alternative Names: MDX-1110; MDX-1204; MDX-1414

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Medarex
  • Class Monoclonal antibodies
  • Mechanism of Action CXCR4 receptor antagonists; Fucosyl GM1 ganglioside inhibitors; Glypican 3 inhibitors; Megakaryocyte potentiating factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
  • 02 Sep 2009 Medarex has been acquired by Bristol-Myers Squibb
  • 27 May 2009 The US FDA approves IND application for MDX-1338 in Acute myeloid leukaemia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top